| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.8 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.8 |